Genflow Biosciences plc has announced a development program in ophthalmology focused on advancing a novel gene therapy leveraging its proprietary centenarian SIRT6 (cSIRT6).

Genflow Biosciences Launches New Ophthalmology Development Program Signs MTA with Leading Ophthalmology Company LONDON, UK / ACCESS Newswire / April 10, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB ...

The company's latest venture involves the use of its proprietary Centenarian SIRT6 (cSIRT6) gene technology, which will be delivered using a non-viral vector specifically designed for targeting ...

This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several ...